MRNA vs TRVI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRNA and TRVI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRNA and TRVI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists that most rivals pursue. Trevi is targeting three indications: chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no marketed products and generates no product revenue, so it funds itself through equity raises and operates at a net loss, which is typical for a company at this stage.

Full TRVI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
• TRVI drivers: Haduvio Phase 3 in IPF-related chronic cough; Refractory chronic cough expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. For TRVI, trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MRNA if you believe its drivers more; TRVI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRNA and TRVI guides.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

TRVI. As a clinical-stage biotech, Trevi has no product revenue and runs at a net loss, so traditional valuation multiples like price-to-earnings do not apply. The roughly $2 billion market capitalization reflects investor expectations for Haduvio's clinical trials rather than current financial performance. The April 2026 capital raise and the resulting projected runway into 2030 are meant to fund the company through its key Phase 3 and Phase 2b readouts.

Headline figures (approximate, July 2026): MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%; TRVI shows market cap ~$2.0 billion, share price ~$13.87, cash and marketable securities (q1 2026) ~$171.8 million, april 2026 offering net proceeds ~$162 million.

MRNA and TRVI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MRNA and TRVI exposure against your real portfolio. It is not an investment adviser.